Takara Biotech Arm To Create Special Stem Cell Research Unit In Japan
This article was originally published in PharmAsia News
Takara Holdings' biotechnology subsidiary, Takara Bio, plans to create a special unit to research and develop induced pluripotent stem cells it hopes will lead to cultivating the material. The new unit is to begin work April 1 with a staff of five researchers to draw on Takara Bio's proprietary method of cultivating lymphocytes. The firm said its goal is to use the stem cells to market new technologies for regenerative medicine, with the possibility of also improving gene- and cell-therapy methods. (Click here for more - a subscription may be required
You may also be interested in...
In this week’s podcast, Medtech Insight's managing editor Marion Webb has an update from the virtual HLTH panel discussions on telehealth and robotics. Deputy editor Reed Miller discusses trial results from Boston Scientific’s next-generation Accurate neo2 self-expanding aortic valve presented during the Transcatheter Cardiovascular Therapeutics (TCT) meeting.
The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.